Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apps Ahead For Diabetes: Q&A With DexCom’s Terry Gregg

This article was originally published in The Gray Sheet

Executive Summary

Continuous glucose monitor developer DexCom is staking its future on an app-based platform for sensor-insulin pump systems. CEO Terrance Gregg offers an update on the company’s efforts, his thoughts on the space and the growing interest in glucose monitoring by big tech firms like Apple and Google.

You may also be interested in...



Big Tech Firms Target Health Care Space With Cheap Sensors In Smartphones

Recent activities by three smartphone giants point to a potential future where the phone itself more frequently serves as a monitoring or diagnosing device, in place of external sensors. If the trend rolls on, it could have important implications for the mobile health sector.

Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue

At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.

Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy

Total ban on background music is unnecessary, agency says in denying KEI’s petition. FDA points to new ‘major statement’ rule and its previous letters objecting to a sponsor’s use of music in ads and says it will continue case by case analysis of ‘all of the elements’ in an ad.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel